Is Retatrutide Safe? Risks, Warnings and Blood Work to Monitor

Is retatrutide safe? In Lilly's trials its side effects look much like those of tirzepatide and semaglutide, mostly stomach trouble, and at the 4 mg dose fewer people quit TRIUMPH-1 over side effects (4.1%) than on placebo (4.9%). Two things stop that from being a clean yes. The longest follow-up is 104 weeks, and nothing sold online is the drug Lilly tested. As of September 2026, no approved version exists anywhere.

The honest answer comes in two parts: the molecule Lilly tested, and the vial someone can buy today. Only the first has trial data behind it.

Is retatrutide safe in clinical trials?

As of September 2026, Lilly has reported 5 Phase 3 trials, with 6,422 people randomized between them. Only TRANSCEND-T2D-1 has a full journal paper so far, in The Lancet, so most numbers below come from Lilly's releases. The cleanest single safety number in each is how many people stopped the drug because of side effects.

Higher doses mostly meant more quitting. TRIUMPH-2 breaks the pattern, with more people stopping 9 mg (11.6%) than 12 mg (7.7%). TRIUMPH-4 looks worst, but Lilly says its quit rates were linked to starting BMI and included people who stopped because they felt they were losing too much weight. Among those who started with a BMI of 35 or more, 8.8% quit on 9 mg and 12.1% on 12 mg, against 4.8% on placebo.

The side effects themselves were the familiar ones. Lilly calls them "generally consistent" with trials of other incretin-based drugs, the family that includes tirzepatide and semaglutide. In TRIUMPH-1, about 4 in 10 people on 12 mg (42.4%) had nausea, against 14.8% on placebo, with diarrhea, constipation and vomiting close behind. Our retatrutide side effects guide breaks those down by dose.

Serious events are harder to pin down, because the Phase 3 releases don't report them. The Phase 2 obesity trial's registry results do: 10 of 267 people on retatrutide (3.7%) had a serious adverse event, against 3 of 70 on placebo (4.3%). Those 10 included one case each of acute pancreatitis, gallbladder inflammation, acute kidney injury and heart failure. In TRANSCEND-T2D-1, The Lancet paper reports 2 deaths, both in the 4 mg group, and the authors judged neither related to the drug.

Our read: 4 mg looks like the gentle end of the range, and 12 mg is where about 1 in 9 people (11.3%) in TRIUMPH-1 quit. How well someone tolerates retatrutide depends a lot on the dose, and that's a conversation for a doctor.

What's different about reta's side effects

One side effect stands out. Burning or oversensitive skin (dysesthesia) hit 5.1%, 12.3% and 12.5% of people on 4, 9 and 12 mg in TRIUMPH-1, against 0.9% on placebo. In TRIUMPH-4 it reached 20.9% on 12 mg, against 0.7% on placebo. For scale, the tirzepatide label lists dysesthesia in 0.2% to 0.4% of people. Those are different trials, so it's a rough comparison, but the gap is wide.

Lilly says these skin events were mostly mild to moderate, most resolved during treatment, and most people kept taking the drug. Our page on retatrutide skin sensitivity covers what it feels like and how long it lasts.

Urinary tract infections were a little more common too: 7.5% to 8.8% on retatrutide in TRIUMPH-1, against 5.3% on placebo.

Then there's pulse. In the Phase 2 trial published in the New England Journal of Medicine, heart rate rose with dose, peaked at 24 weeks and declined after that. The tirzepatide label reports an average rise of 1 to 3 beats per minute, which is class evidence, not retatrutide data. Our retatrutide heart rate page has the detail.

Is reta dangerous for your heart?

The best evidence so far comes from TRIUMPH-3, which enrolled 1,949 people with severe obesity and established heart disease, the group where a heart problem would be most likely to show up. Over 80 weeks, 44 people on retatrutide and 52 on placebo had a major heart event (death from any cause, heart attack, stroke, a heart failure event or a procedure to reopen a heart artery). For the narrower set of cardiovascular death, heart attack or stroke, it was 27 against 23.

Neither result is a clear win or loss. The hazard ratios were 0.82 and 1.12, and both ranges of uncertainty cross 1 (0.55 to 1.22, and 0.64 to 1.96). Lilly also says these events happened less often than expected in both groups, which leaves the trial short of events to judge by.

The risk factors moved the right way. In TRIUMPH-1, systolic blood pressure fell by up to 12.3 mmHg and triglycerides by up to 41.0%. The trial built to settle the heart question, TRIUMPH-Outcomes, covers an estimated 10,000 people with heart or kidney disease, and its ClinicalTrials.gov record puts its primary completion in February 2029.

Rare problems the labels warn about

Retatrutide has no label yet, so the closest guide is tirzepatide's, which shares two of its three hormone targets. Its FDA label warns about:

• pancreatitis, with severe belly pain that won't go away and may spread to the back
• gallbladder problems, with upper belly pain, fever or yellow skin or eyes
• kidney injury from dehydration, mostly in people losing fluid through vomiting or diarrhea
• low blood sugar when combined with insulin or a sulfonylurea
• food in the lungs during anesthesia or deep sedation, because the stomach empties slowly

It also carries a boxed warning about thyroid C-cell tumors, including medullary thyroid cancer. The label says it's unknown whether tirzepatide causes them in people, and no retatrutide data answers that yet. TRIUMPH-1 excluded anyone with a personal or family history of medullary thyroid cancer. Our pancreatitis and gallbladder page goes further.

Is reta peptide safe when it's bought online?

This is where the real harm has shown up. Lilly's position is blunt: no one should take anything claiming to be retatrutide outside a Lilly-sponsored trial. It warns that such products may contain unknown ingredients, contaminants, too much or too little active drug, or the wrong drug entirely, and it says retatrutide "cannot be legally sold or marketed for human use."

The FDA says retatrutide can't be used in compounding under federal law. It has warned telehealth companies that marketed it, and sellers who labeled vials as not meant for people while selling them to consumers with dosing instructions.

Then came Victoria. On June 19, 2026, the state's Chief Health Officer reported 6 cases of acute liver injury since January in people using products labeled Retatrutide, bought online, through friends or on social media. The department said the pattern suggests a contaminant may be contributing, and told anyone still using these products to have a GP consider liver function tests.

Compare that with the trial molecule. In a Phase 2 substudy of 98 people with fatty liver disease, published in Nature Medicine, liver fat fell by 82.4% on average at 24 weeks on 12 mg, and the authors saw no signs of liver toxicity in the substudy or the full trial through 48 weeks.

Our read: a drug that cut liver fat with no liver-toxicity signal in trials doesn't fit a run of liver injuries, which points at what else was in those vials. Victoria's health department suspects the same.

Wrong contents have already been caught in a lab. In a safety alert published September 14, 2026, Australia's Therapeutic Goods Administration (TGA) described a person who had uncontrollable vomiting and a torn esophagus after using a product sold as retatrutide. Its test of the vial found no retatrutide, just undeclared semaglutide at about 8 times the level in approved semaglutide products.

If you're still weighing retatrutide for sale online, the minimum bar is a batch-specific third-party test for identity, purity, amount per vial and endotoxin, with a batch number that matches your vial. Even that can't make a vial into the product Lilly tested, and dosing errors add their own risk.

Who should not take retatrutide

With no retatrutide label, two sources fill the gap: who Lilly kept out of its trials, and who the tirzepatide label warns off. Take this list to a doctor.

• Anyone with a personal or family history of medullary thyroid cancer or MEN 2. TRIUMPH-1 excluded them, and tirzepatide is off-limits for them.
• Anyone who has had pancreatitis. TRIUMPH-1 excluded them.
• Anyone pregnant or trying. The tirzepatide label says it may harm an unborn baby, and no retatrutide pregnancy data has been published. That label also tells people on the pill to switch or add a barrier method for 4 weeks after starting and after each dose increase.
• Anyone under 18. The trials enrolled adults only.
• People on insulin or a sulfonylurea, because of low blood sugar risk, and people with diabetic eye disease, which the tirzepatide label says needs watching.
• Anyone with weight-loss surgery behind them. TRIUMPH-1 excluded that group too, so there's no data.

Blood work and checks to ask your doctor about

Nobody has published a monitoring schedule for retatrutide. The table pulls together what the tirzepatide label and Victoria's health department actually say.

On r/Retatrutide, some blood work threads report liver enzymes going up and others report them going down. Those are single stories about products of unknown content, not a study.

Retatrutide pros and cons

What nobody knows yet: how retatrutide behaves past 104 weeks, and what the full serious-event tables for TRIUMPH-1 through 4 show. As of September 2026, Lilly plans to file for US approval in Q1 2027, and none of those four trials has a full journal paper yet. For how the trials paced each dose, see our retatrutide dosage page, and for what longer use could bring, see long-term side effects.

Until approval, Lilly says retatrutide is "legally available only to participants in Lilly's clinical trials." As of September 2026, ClinicalTrials.gov lists 33 retatrutide records but only 2 recruiting, and 1 of those isn't a Lilly trial. The Lilly one, SYNERGY-Outcomes, is for adults with fatty liver disease at higher risk of liver complications.